Workshop 20
Antiviral therapy and resistance II

Programm

• 10:45 – 11:00 12 Min. 3 Min.

  • Abstract talk
  • O 111

  Development of a Nanobody-Drug Conjugate Targeting Host Protease Furin for Antiviral Therapy

  • Konstantin Bloch (Marburg / DE)

   Antiviral therapy and resistance
• 11:00 – 11:15 12 Min. 3 Min.

  • Abstract talk
  • O 112

  Novel vidofludimus-based DHODH inhibitors containing carboxylic acid bioisosters with superior broad-spectrum antiviral activity

  • Dr. Alexandra Herrmann (Erlangen / DE)

   Antiviral therapy and resistance
• 11:15 – 11:30 12 Min. 3 Min.

  • Abstract talk
  • O 113

  Analysis of the metabolome of varicella zoster virus infected cells reveals One-Carbon metabolism as a therapeutic target to inhibit infection

  • Josephine Schenk (Hanover / DE)

   Antiviral therapy and resistance
• 11:30 – 11:45 12 Min. 3 Min.

  • Abstract talk
  • O 114

  Inhibition and Specific Targeting of Virus Infected Cells by Cytolytic VSVΔG Carrying Viral Receptors

  • Dr. Fabian Zech (Ulm / DE)

   Antiviral therapy and resistance
• 11:45 – 12:00 12 Min. 3 Min.

  • Abstract talk
  • O 115

  Optimisation of mRNA encapsulated Lipid nanoparticles (LNPs) for in vivo administration of monoclonal antibodies

  • Hanife Dinc (Erlangen / DE)

   Antiviral therapy and resistance
• 12:00 – 12:15 12 Min. 3 Min.

  • Abstract talk
  • O 116

  Identification and development of Sudan virus VP40 inhibitors with promising pan-filovirus activity using a crystallographic high-throughput screening

  • Dr. Anke-Dorothee Werner (Marburg / DE)

   Antiviral therapy and resistance